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Abstract
Advances in flow cytometry and other single-cell technologies have enabled high-dimensional, 
high-throughput measurements of individual cells and allowed interrogation of cell population 
heterogeneity. Computational tools to take full advantage of these technologies are lacking. Here, 
we present COMPASS, a computational framework for unbiased polyfunctionality analysis of 
antigen-specific T-cell subsets. COMPASS uses a Bayesian hierarchical framework to model all 
observed functional cell subsets and select those most likely to exhibit antigen-specific responses. 
Cell-subset responses are quantified by posterior probabilities, while subject-level responses are 
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quantified by two novel summary statistics that can be correlated directly with clinical outcome, 
and describe the quality of an individual’s (poly)functional response. Using three clinical datasets 
of cytokine production we demonstrate how COMPASS improves characterization of antigen-
specific T cells and reveals novel cellular correlates of protection in the RV144 HIV vaccine 
efficacy trial that are missed by other methods. COMPASS is available as open-source software.
Introduction
Recent technological advances in both flow and mass cytometry assays have transformed 
the field of immunology by enabling dozens of parameters to be quantified at the single-cell 
level in a high-throughput fashion. Increasing numbers of studies and clinical trials now rely 
on these assays to provide multi-parameter single-cell measurements, and functional 
evaluation is shifting from the analysis of single markers to these multidimensional 
measurements. In particular, single-cell analyses by intracellular cytokine staining (ICS) – a 
type of flow cytometry assay (Figure 1) – have become important tools to characterize 
subsets of antigen (Ag)-specific T cells capable of simultaneously producing multiple 
effector cytokines and other functional markers, termed polyfunctional T cells1. 
Polyfunctional T cells have been shown to play an important role in protective immunity 
and non-progression of diseases, and to correlate with better clinical outcomes in certain 
settings2–4. Vaccination in humans can generate broad T-cell cytokine responses5,6, thus, 
polyfunctional T-cell subsets are attractive potential biomarkers; however, effective 
statistical tools for analyzing the complexity of these immune responses are lacking.
Although many analytic tools exist for cytometry-based assays7–9, very few tools have been 
developed specifically for the analysis of high dimensional ICS data. Existing strategies are 
in their infancy and remain basic and low dimensional, ranging from ad-hoc rules based on 
fold-changes10, Hotelling’s T2 statistics11, and 2×2 contingency tables12,13, to simple 
graphical displays of summary statistics7. In most ICS assays, the frequencies (and thus cell 
counts) of Ag-specific subsets are very small (e.g., less than 0.1% of total T cells), rendering 
statistical analysis difficult. This problem only worsens as these cells are further partitioned 
based on co-expression of multiple cytokines. In addition, multiple comparisons across 
subjects and cell subsets must be taken into consideration and can reduce statistical power. 
Due to the lack of proper analytical tools, studies have been limited to formal statistical 
comparisons of only a few functions, and most of the work on polyfunctionality has been 
phenomenological.
To address some of these limitations, Finak et al.14 have proposed a framework based on 
mixtures of beta-binomials named MIMOSA (MIxture MOdels for Single-cell Assays). 
MIMOSA rigorously analyzes count data derived from ICS assays. However, MIMOSA was 
mainly developed for univariate analysis of cell subsets, such as cells expressing a single 
function or a specified combination of functions. Although MIMOSA includes a 
multivariate version, Finak et al. we were solely interested in making positivity calls 
irrespective of the qualitative aspect of the response, and as such the output is still univariate 
(probability of response). More importantly, in order to apply the MIMOSA framework to 
multivariate data, the authors had to make the assumption that there is measurable antigen-
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specific response across all functional subsets, but this assumption is simply incorrect in 
practice. Different antigens usually induce very different functional profiles and many of the 
possible functional cell subsets are not expected to be associated with antigen-specificity. 
MIMOSA cannot jointly model all subsets to identify distinct Ag-specific responses, yet this 
is particularly important as the number of definable subsets grows exponentially with the 
number of cytokines analyzed. As an example, an ICS experiment measuring 7 functions 
can define 128 Boolean cell subsets, but only a fraction of those are expected to be 
biologically relevant (e.g., not all combinations respond to a specific antigen). A possible 
solution would be to model and test each subset separately but this is computationally 
intensive, ignores the dependence between subsets, and leads to extreme multiple testing 
problems. In the interest of decreasing the number of variables while taking into account the 
degree of functionality, Larsen et al. have introduced a Polyfunctionality Index (PI)15 that 
aims to facilitate statistical analysis and correlation with clinical outcome by summarizing 
the polyfunctional profile into a single number. However, the PI uses empirical proportions, 
which are known to be extremely noisy when cell counts are small, and combines 
information from all cell subsets, including non-specific ones, thus masking real signal. 
Indeed, many of the functional subsets that are not antigen-specific will often exhibit a 
significant background level, and the inclusion of these will make the defined index more 
variable. This still remains true even after background correction (using a negative-control) 
due to sampling and assay variability. In addition, by weighting the subsets by their 
magnitude, low-magnitude (but potentially important) subsets will be down weighted 
significantly. As such, the PI falls short of describing the true breadth of polyfunctionality, 
ultimately limiting its clinical utility (as we will show later). An ideal framework for the 
analysis of T cells should identify and quantify changes in (possibly rare) Ag-specific cell 
subsets and permit the definition of different qualities of a (poly)functional response such as 
summary statistics that can be correlated with outcomes of interest.
In order to address these needs, we have developed COMPASS (Combinatorial 
Polyfunctionality analysis of Antigen-Specific T-cell Subsets), which uses a Bayesian 
hierarchical mixture model to permit the identification of Ag-specific changes across all 
observable T-cell subsets simultaneously, enabling the definition of subject-specific and 
cohort-specific Ag-specific T-cell profiles that can be summarized and correlated to 
outcomes of interest. This method jointly models all cell subsets, regularizes small cell 
counts, and allows information sharing across all subjects through the calculation of subset-
specific posterior probabilities that can be used to automatically detect and quantify Ag-
specific subsets. COMPASS uses a novel, computationally efficient Markov Chain Monte 
Carlo algorithm to explore the space of all possible functional T-cell subsets and to compute 
the subset-specific posterior probabilities. These probabilities naturally account for multiple 
testing16 and permit the derivation of a false discovery rate estimate through a direct 
posterior probability approach17. COMPASS provides two novel scores: the functionality 
(FS) and the polyfunctionality (PFS) scores that can be correlated with any clinical outcome 
of interest. These scores summarize, as a single number for each subject, the posterior 
probabilities of Ag-specific response across cell subsets. Here we apply this new method to 
three ICS data sets: the RV144 HIV vaccine case-control study18,19, a cross-sectional study 
of South African adolescents infected with Mycobacterium tuberculosis (MTB)20 and a 
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phase 1b trial from the HIV Vaccine Trials Network21. We use these datasets to demonstrate 
the ability of COMPASS to identify specific (poly)functional responses that are correlated 
with clinical outcomes of interest.
Results
COMPASS enables the unbiased quantification of polyfunctional cell subsets
Here we reanalyzed the ICS data generated through the RV144 HIV vaccine case-control 
study with 92TH023-Env peptide pool ex vivo stimulation as described in the Methods and 
in a prior publication18. Expression of a set of six functions (IFNγ, TNFα, IL2, IL4, IL17 
and CD40L) was measured in CD4+ T cells by ICS (n=226 vaccine and n=36 placebo 
recipients). We used COMPASS to define 64 functional cell subsets from the Boolean 
combinations of the individual cytokines expressed in each cell. Only 24 of these had non-
negligible (>5 cells in >2 subjects) cell counts and were considered for analysis. Arguably, if 
there are only two subjects with no more than five cells in any cell subset then it would be 
difficult to detect antigen-specific response, and we feel that these values should be 
reasonable for most ICS datasets. In addition, changing these cutoffs to be less stringent had 
no impact on the significance of the results or conclusions presented here, and is purely for 
computational convenience to reduce the time needed to fit a COMPASS model to cell 
subsets that contain no signal. In Figure 2a, a heatmap displays posterior probabilities of Ag-
specific responses from COMPASS for these T-cell subsets and demonstrates that while 
some Ag-specific subsets are universally present in almost all vaccinees (e.g., IL2 & 
CD40L), others exhibit heterogeneity across subjects (e.g., the four- and five-function 
subsets). These findings support the need for unbiased polyfunctionality analyses that can 
provide insights on the possible association between polyfunctional Ag-specific T cells and 
vaccine efficacy.
ICS assays are often used to identify vaccine responders based on the magnitude of Ag-
specific T-cell responses, although current approaches tend to be univariate. COMPASS can 
identify vaccine responders by computing subject-level response probabilities for each 
subject (Online Methods). We compared COMPASS with the two standard approaches for 
designating positivity, Fisher’s exact test12, and MIMOSA14 using the primary endpoint in 
the original RV144 analysis18 as well as the multivariate MIMOSA and the 
polyfunctionality index (PI) (Online Methods). A receiver operating characteristic (ROC) 
analysis shows that COMPASS significantly increases sensitivity and specificity when 
discriminating between vaccine and placebo recipients compared to all other approaches 
(Supplementary Figure 1).
In addition to subject-level response probabilities, COMPASS defines two new scores that 
summarize a subject’s entire Ag-specific polyfunctional profile into a single numerical value 
(Figure 2b). The functionality score is defined as the proportion of Ag-specific subsets 
detected among all possible ones. The polyfunctionality score is similar, but it weighs the 
different subsets by their degree of functionality, naturally favoring subsets with higher 
degrees of functionality, motivated by the observations that higher degree function has been 
correlated with good outcomes in certain vaccine studies5,6 (See Online Methods for 
details). Figure 3a shows that the functionality score is well correlated with the number of 
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functions (secreted cytokines) as measured by multiplex bead array on the same set of 
samples from the RV144 case-control study (correlation ρ=0.69, p-value < 2.2×10−16, 95% 
confidence interval (CI) = (0.62, 0.75)), suggesting that COMPASS detects true Ag-specific 
responses in T-cell subsets. Out of the 12 cytokines measured by a multiplex bead array, 
only four were also measured by ICS (IFNγ, TNFα, IL2, IL4). Subjects with high 
functionality scores also express many other cytokines not measured in the ICS assay. We 
also tried to restrict the analysis to the four common cytokines but it did not improve the 
correlation, in fact it decreased slightly to 0.65. Figure 3b shows that the functionality score 
is also significantly correlated with HIV Env-specific antibody binding in plasma 
(correlation ρ=0.41, p-value=9.87×10−11, 95% CI = (0.30, 0.52)). In addition, 
Supplementary Figure 2 shows that the placebo recipients have much smaller FS and PFS 
scores compared to vaccine recipients, and that the PI is noisier than the FS and PFS scores. 
All together, these data indicate once again that our FS and PFS scores are good at capturing 
and summarizing a subject’s response to vaccination. These results were also confirmed 
with the RV144 pilot data, used to inform the selection of assays to be used for the case-
control study, thus providing validation from an independent set of subjects (Supplementary 
Figures 3–6). Using boxplots of the functionality and polyfunctionality scores for RV144 
broken down by infection status (Figure 2b), it can be seen that these two scores vary greatly 
by subject, and that on average non-infected subjects have higher scores than infected 
individuals and that these effect are stronger for the polyfunctionality score (Wilcoxon test p 
= 0.03 (FS), p = 0.01 (PFS)).
COMPASS identifies novel cellular correlates of infection risk in RV144 vaccinees
Among the 17 different types of immune assays and their 152 component variables used to 
assess correlates of infection risk in RV144, 6 assays (including ICS CD4+ T-cell responses) 
were chosen as primary variables as having optimal statistical power when adjusting for 
multiple comparisons18 (see Online Methods for primary analysis results). The major 
findings in a multivariate model including all six primary variables were that gp70-V1V2-
specific plasma IgG inversely correlated with infection rate (odds ratio 0.57, p=0.02, 
q=0.08), and Env-specific plasma IgA was a direct correlate of infection (odds ratio 1.54, 
p=0.03, q=0.08). No CD4+ T cell cellular correlates were identified in the primary analysis 
in the original study. In contrast, using the same method as in the original correlate 
analysis18 (also see Online Methods) but including the functionality and polyfunctionality 
scores rather than the primary CD4+ T cell endpoint variable, the polyfunctionality score 
was inversely correlated with infection (p = 0.005, q=0.05, Table 1), as was the functionality 
score but to a lesser extent (p=0.01, q=0.06, Table 1). This correlation is also supported by 
the fact that the number of functions (secreted cytokines) as measured by multiplex bead 
array is also inversely correlated with infection (p=0.013, Supplementary Table 1). 
However, the multiplex bead array data do not permit polyfunctionality analysis since it is 
an assay performed on bulk cells, and as such the co-expression of multiple cytokines cannot 
be measured at the single-cell level. Our COMPASS PFS score suggests that polyfunctional 
Ag-specific CD4+ T-cells might have played a role in vaccine efficacy. To identify the 
specific cell subsets that most contributed to this correlation, each subset of interest as 
shown in Figure 2a was evaluated as a correlate for infection risk. Two Ag-specific T-cell 
subsets were significantly correlated with infection (q≤0.1, Table 1). It can be seen that the 
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polyfunctional subset expressing CD40L, IL2, IL4, IFNγ and TNFα shows the most 
significance (OR=0.58, p=0.006, q=0.05) followed by a three-function subset (CD40L, IL2, 
and IL4, OR=0.62, p=0.01, q=0.06). The 5-degree subset is as significant as the previously 
reported gp70-V1V2 correlate. Importantly, these subsets were identified in an unbiased 
way rather than by limiting our analysis to very specific subsets based on expected 
biological relevance as was done in the original study. Interestingly, both subsets include 
IL4 and CD40L, a cytokine and functional marker important for the CD4 T cell/B cell 
interaction. Thus, these particular CD4+ T-cells subsets may contribute the T-cell help 
necessary for the antibody production detected as a correlate in the primary analysis. All 
subsets, including non-significant ones, are presented in Supplementary Table 2. In addition, 
we have also assessed the magnitude of response for all functional subsets (Supplementary 
Table 3) as well as the PI and MIMOSA scores (Supplementary Table 1) as individual 
correlates of risk, and none of these variables were significant. The superiority of 
COMPASS is also supported by an ROC analysis using the predicted infection probabilities 
from a logistic regression model (Supplementary Figure 7).
Mycobacterium tuberculosis (MTB) infection induces highly polyfunctional responses
We used COMPASS to investigate polyfunctionality in CD4+ T cells obtained from a South 
African study of 18 MTB-uninfected and 22 MTB-infected subjects. Subjects were 
classified as TB-infected as described in the Methods section and in the original study20. T 
cells were stimulated with MTB-specific22 and non-specific peptide pools, and a set of 
seven cytokines/functional markers (see Methods) was measured by ICS, with 22 Boolean 
combinations defined for COMPASS analysis.
Figure 4a shows a heatmap of posterior probabilities of Ag-specificity with subjects color-
coded by the specificity of the peptide stimulation (MTB-specific and MTB non-specific). 
Figure 4b shows boxplots of the functionality and polyfunctionality scores broken down by 
TB infection status and stimulation. As expected, CD4+ T-cell responses to MTB-specific 
proteins were largely absent from MTB-uninfected subjects. Ex vivo stimulation with MTB-
specific antigens induces strong Ag-specific responses spread across polyfunctional subsets 
of degree three and five in MTB-infected subjects. In contrast, MTB-uninfected subjects 
have weak responses in these subsets. The appearance of the five-degree subset (IL17α, 
CD40L, IFNγ, TNFα and IL2) in some MTB-uninfected persons may represent a more 
sensitive marker of infection or may simply be a false positive result. Further study will be 
required to distinguish among these possibilities. In contrast, the response to non-specific 
mycobacterial peptides is concentrated over one subset expressing IFNγ, IL2, TNFα and 
CD40L, and is independent of a subject’s MTB status. This response to non-specific 
mycobacterial proteins is likely due to BCG vaccination or environmental exposure to non-
tuberculous mycobacteria.
As can be seen in Figure 4a, COMPASS detects MTB-specific responses for some cell 
subsets that do not include IFNγ, suggesting that such analysis may add value to standard 
QFT analyses in identifying patients with MTB infection. Given this observation, we 
assessed whether COMPASS could be used to classify MTB-uninfected and MTB-infected 
subsets and how this would compare to a classification based on marginal IFNγ response 
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alone, essentially a surrogate for the QFT. Supplementary Figure 8 shows an ROC analysis 
comparing COMPASS to various summary statistics based on the IFNγ response including 
MIMOSA, Fisher’s exact test and background corrected empirical proportions of IFNγ+ 
cells, as well as the multivariate MIMOSA and the PI. These data demonstrate that using 
COMPASS’ polyfunctional profile to classify subjects as MTB infected vs. uninfected 
provides increased sensitivity and specificity compared to using IFNγ alone or the PI. The 
lack of total concordance between the QFT and ICS IFNγ response may be explained by 
differences between fresh whole blood and frozen PBMC used for the two assays, the lack 
of TB7.7 in the ICS assay, and measurement of IFNγ expression (ICS) vs secretion 
(ELISA).
COMPASS identifies functional differences between vaccine regimens missed by 
traditional analyses
As a third example, we applied COMPASS to ICS data from a clinical trial of candidate 
HIV vaccines23 to determine if a polyfunctionality analysis could unveil differences missed 
in the primary analysis (see Methods). The combination of heterologous vectors has proven 
to be a good strategy to increase immune responses to vaccination24, which is particularly 
relevant for HIV where there is not yet an effective, licensed vaccine. Bart et al.21 showed 
that priming with rAd5 followed by NYVAC boost resulted in increased percentage of Ag-
specific T cells producing IL2 and/or IFNγ compared to NYVAC followed by rAd5, but that 
higher doses of rAd5 prime did not lead to any increased response. Figure 5a shows a 
heatmap of the posterior probabilities for all CD4+ T-cell Boolean subsets considered. While 
this heatmap supports the findings of Bart et al., it also shows that increasing dosage of 
rAd5 led to a decrease in overall response, which is nicely summarized by the FS and PFS 
scores (Figures 5b). Although T3 and T4 have comparable FS and PFS scores, it is notable 
from Figure 5a that very few subjects in T4 produce Ag-specific T cells co-expressing IL4/
IFNγ/TNFα/CD40L compared to T3. This is confirmed when the probability of response for 
this subset is plotted separately (Supplementary Figure 9). This suggests that a difference in 
dosage can lead to substantial qualitative differences in immune responses after vaccination 
(p-value = 0.004 for Fisher’s exact test on proportions of responders between T3 and T4).
Discussion
These three examples highlight the ability of COMPASS to reveal differences in the quality 
of an immune response that were not evident using standard approaches. It remains 
uncertain as to whether specific cellular subsets of unique polyfunctional profiles have 
clinical significance, for example, in terms of mediating protection from disease. The 
RV144 data set provided an opportunity to investigate association between subset detection 
and a clinical endpoint, HIV infection. Indeed, two vaccine-induced polyfunctional CD4+ T-
cell subsets not identified in the prior analyses were shown to associate with decreased risk 
of HIV infection. Although the original cellular endpoint in RV144 was not designed to 
detect polyfunctional responses, current tools used to assess polyfunctionality are inadequate 
and miss this association. The TB study also allowed for association of cellular subsets with 
a clinical outcome, presence or absence of MTB infection. In this case, the diagnostic 
methods for determining infection are not definitive, and our approach has the potential for 
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augmenting diagnostic methods. The third example applied in the context of a phase I 
clinical trial does not have a clinical endpoint, but the striking difference in one four-
function subset between two identical vaccine regimens that differ only in dose raises 
questions about the functional significance of this subset, or at a minimum, the potential of 
this subset as a future correlate of vaccine efficacy.
COMPASS analysis of the tuberculosis dataset revealed two findings that would likely have 
been missed using standard methods of analyzing multiparameter FACS data. First, we 
demonstrate the presence of a polyfunctional CD4+ T-cell subset recognizing MTB-specific 
proteins that does not include IFNγ yet was preferentially detected among MTB-infected 
subjects. IFNγ release assays are the clinical standard for diagnosis and are still imperfect25, 
so this observation may have important implications for the design of improved diagnostics. 
Second, we demonstrated the presence of a T-cell subset that simultaneously produced 
IL17A, IFNγ, CD40L, IL2, and TNFα in response to MTB-specific proteins among MTB-
infected subjects. To our knowledge, this has not been previously reported and it is not clear 
if such highly-polyfunctional T cells are important for protection from tuberculosis, but the 
analysis of RV144 data presented here would suggest this is possible. The availability of 
COMPASS will make it easier to analyze phase 2 studies of TB vaccines currently 
underway for the association of these subsets with clinical outcomes. Finally, only a small 
proportion of MTB-infected individuals will eventually develop active tuberculosis, so the 
stratification of MTB-infected subjects into different T-cell response categories could be 
utilized to predict which individuals are at highest risk of progression to active TB disease.
The two functionality and polyfunctionality scores introduced in this paper provide unique 
T-cell response summaries that can be used to quantify a subject’s immune response and be 
used as a biomarker to be correlated with a given outcome. Although the score definitions 
are related, and thus the scores expected to be correlated, we believe that the two scores are 
complementary and provide additional information versus one score alone. For example, 
even though the correlation between the two scores in the RV144 case-control study is 0.95, 
we have shown that while the functionality score was better correlated with other cellular 
and antibody functions as measured by multiplex bead array assay, the polyfunctionality 
score provided a better correlate of protection. In addition, multivariate response profiles 
based on the posterior probabilities returned by COMPASS, were helpful in singling out 
specific subsets that were associated with specific treatment groups or clinical variables. 
Other published studies have also reported similar findings26–28, reinforcing the need for 
unbiased, multivariate analyses. It should be noted, however, that since COMPASS analyzes 
and reports probabilities for all functional subsets, the results could be prioritized and/or 
summarized in reference to cytokine-based functionalities (e.g. Th1, Th2, Th17, etc).
These findings reinforce the idea that the quality rather than the magnitude of T-cell 
responses is more important for determining the outcome of infection or response to 
vaccination29. We think that for the purpose of summarizing the functionality or 
polyfunctionality over all subsets, it is preferable to define a variable that does not include 
the magnitude of the response; otherwise the large-magnitude subsets would mask the low-
magnitude ones. This is particularly important since the magnitude of high-degree (i.e. 
polyfunctional) subsets is typically smaller. This being said, our functionality and 
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polyfunctionality scores do take into account the magnitude of response up to a certain 
point, after which the subsets are treated equally (when the model judges that there is a 
significant increase upon stimulation and we are certain of the specificity of the response). 
Also, because our approach is model based, the relationship between the magnitude and the 
probability of antigen-specificity takes into account the uncertainty in the observed cell 
counts (Supplementary Figure 10), such that cell subset with greater background will have 
lower response probabilities, even at comparable magnitude. Although we could use the 
actual proportion of Ag-specific cells in our calculation, we have found that it did not add 
any predictive value (Supplementary Figures 11–12, Supplementary Table 4). This could be 
explained by the fact that the actual magnitude of the proportion is not that important in 
terms of clinical outcome, i.e. what matters is the quality of the Ag-specific response and not 
the quantity of Ag-specific T cells, or that the estimates of proportions are too noisy to be 
meaningful when the overall proportion of Ag-specific cells is small, which is clearly the 
case for HIV and TB. However, if one really wants to look at the magnitude, we think that it 
might be better quantified at the subset level, which can easily be done with COMPASS 
since it models all subsets jointly.
The development of statistically sound methods for the characterization of Ag-specific T 
cells from single-cell assays is becoming increasingly important as the underlying 
technologies are improving, leading to a combinatorial explosion of the number of 
functionally distinct subsets that can be defined from an experiment. As we have shown, 
standard approaches that ignore the multivariate nature of ICS data can be quite sub-optimal, 
as they will likely miss rare but important signals. This problem will only get worse as new 
high-dimensional single-cell technologies such as CyTOF, multiplexed-qPCR and RNA-seq 
become more widely used. Although our approach was developed primarily for flow 
cytometry based ICS assays, it is directly applicable to CyTOF-based ICS experiments, and 
should be generalizable to other assay technologies including multiplexed-qPCR and single-
cell RNA-seq.
COMPASS is available as an R package (http://www.github.com/RGLab/COMPASS) and 
provides an interactive, web-based interface for visualizing all data and results. All data and 
results presented in this paper can be visualized through a web-tool available at: http://
rglab.github.io/COMPASS/.
Online Methods
Data for these studies derive from three clinical protocols that were approved by the relevant 
institutional review boards. All study participants provided written informed consent for 
immune response exploratory analyses.
RV144 case-control dataset—HIV negative healthy volunteers enrolled in the RV144 
trial (ClinicalTrials.gov registration number NCT00223080) were vaccinated at weeks 0, 4, 
12, and 24, and immune responses at week 26 were evaluated as immune correlates of 
infection risk through a case-control analysis18,19. A total of 246 vaccinated subjects were 
used for this analysis: 41 subjects who acquired HIV-1 infection (cases) after week 26 and 
205 frequency matched subjects who did not become infected over the follow-up period 
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(controls). A total of 17 types of immune assays were run on the case-control samples. In 
addition, these assays were also performed on random samples from 40 placebo recipients 
(20 cases and 20 controls). The analysis presented here, focused on assessing poly-
functional HIV-1 envelope proteins (Env)-specific T-cell response using ICS, one of the 17 
available assays. As a mean to validate our analysis and explore relationships between 
cellular and antibody functions, we also correlated our ICS responses with two other assays: 
a multiplex cytokine bead array measuring antigen-specific cytokine secretion in PBMCs, 
and a binding antibody multiplex assay measuring IgG binding to HIV-1 envelope proteins. 
After removing missing data due to assay failure, we ended up with 226 vaccinated subjects 
(38 infected, 188 non-infected) with complete data across the three assay types.
ICS—In this dataset, a set of 6 functions: TNFα, IFNγ, IL4, IL2, CD40L and IL17A were 
measured at the single-cell level in CD4+ T cells in the presence and absence of stimulation 
with a peptide pool matching one of the HIV-1 envelope proteins contained in the vaccine 
(92TH023). Cell level data were extracted from raw data files using the analysis described in 
Haynes et al. (2012)18, leading to the definition of count data for the 26=64 theoretical 
Boolean subsets for each subject and stimulation condition. However, the actual number of 
observed (i.e. non-empty) cell subsets is 59, and we further filtered out subsets that had 
fewer than six cells in fewer than three subjects, reducing that number to 24.
Multiplex cytokine bead array—A set of 12 cytokines (IFNγ, IL4, IL2, IL5, TNFα, 
IL10, TNFβ, IL13, MIP1β, GM-CSF, IL3, IL9) were measured using multiplex bead array 
technology. For each subject and cytokine, the response is defined as the difference in log 
concentration between the stimulated (92TH023-Env) and un-stimulated samples. For each 
subject, individual cytokines were called positive/negative using the thresholds defined in 
the original study18.
IgG total binding—Binding IgG antibodies to the envelope (Env) protein of the HIV virus 
were measured using a binding antibody multiplex assay. Here, we used the IgG total 
binding response to Env defined as the mean binding IgG to multiple Env proteins18.
Pilot data—As part of the RV144 case-control study, the 17 assay types used in the case-
control study were selected from 32 pilot assay types on the basis of reproducibility, ability 
to detect post vaccine responses, and uniqueness of responses detected, from which 6 
primary assay variables were selected for the correlate analysis. ICS and multiplex bead 
array were two of the assays types that were evaluated during the pilot phase. All samples 
used in the pilot phase were from non-infected subjects. For ICS, 36 placebo and 119 
vaccine recipient (60 pre and 59 post vaccination) samples were used. For multiplex bead 
array data, 30 placebo and 98 vaccine recipient (57 pre and 41 post vaccination) samples 
were used.
TB data set—We obtained cryopreserved PBMC from an epidemiologic study of South 
African adolescents who were screened for the presence of latent tuberculosis infection 
(LTBI) using tuberculin skin testing and QuantiFERON-TB GOLD in tube testing of whole 
blood20. This dataset includes 40 subjects, 22 MTB-infected and 18 MTB-uninfected. 
Subjects were classified as MTB-infected using both TB skin testing and the Quantiferon 
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test in-tube gold (QTF-gold) that measures IFNγ release in whole-blood after stimulation 
with ESAT-6, CFP-10 and TB7.7 peptides25. PBMCs were plated at a density of 2E5 per 
well and stimulated for six hours with either DMSO or peptide pools consisting of 15mers 
overlapping by 12 peptides for the following mycobacterial proteins: ESAT-6, CFP-10, 
TB10.4, Ag85A, and Ag85B at a final concentration of 1mcg/ml. Cells were stained using a 
published panel in which we replaced MIP-1b and CD107a with IL-17a Alexa 700 and 
IL-22 PE Cy712,30. Analysis of CD3+CD4+ events was performed in FlowJo (TreeStar Inc.) 
after first gating on single cell events, CD14− events, live cells, and lymphocytes. For the 
purposes of analysis, we pooled counts obtained after stimulation with ESAT-6 and CFP-10 
and defined this as ‘MTB-specific’ because these proteins are known to be absent in 
Bacillus Calmette-Guérin (BCG) and many environmental mycobacteria. By extension, 
counts obtained after stimulation with Ag85A, Ag85B, and TB10.4 were pooled and defined 
as ‘MTB-nonspecific’ because these proteins are present in M. tuberculosis as well as BCG 
and many environmental mycobacteria. Seven functions were measured at the single-cell 
level in CD4+ T cells: TNFα, IFNγ, IL4, IL2, CD40L, IL17A and IL22 leading to 128 
theoretical subsets. However, the actual number of observed cell subsets was 79, and using 
the filtering criteria described above we reduced that number to 22 (MTB-specific) and 19 
(MTB-non-specific).
HVTN078—HVTN 07821 is a randomized, double-blind phase 1b clinical trial 
(ClinicalTrials.gov registration number NCT00961883) to evaluate the safety and 
immunogenicity of heterologous prime/boost vaccine regimens (NYVAC-B/rAd5 vs. rAd5/
NYVAC-B) in healthy, HIV-1 uninfected, Ad5 seronegative adult participants. Eighty 
participants were enrolled into one of four groups receiving different combinations of 
NYVAC-B (New York Vaccinia [NYVAC] vector containing HIV-1BX08 gp120 and 
HIV-1IIIB gag-pol-nef at a dose of 1×107 PFU) and rAd5 (HIV-1 recombinant adenoviral 
serotype 5 [rAd5] vector vaccine VRC-HIVADV014-00-VP [(HIV-1HXB2/NL4-3 Gag-Pol 
fusion; HIV-192RW020, HIV-1HXB2/Bal and HIV-197ZA012 Env], at three increasing 
doses [1×108, 1×109, 1×1010 PFU]). We refer to the four different groups as T1, T2, T3 and 
T4. In the T1 group, NYVAC was the prime with rAd5 as the boost, while subjects in T2–
T4 received rAd5 as the prime and NYVAC as the boost with the three increasing doses of 
the prime. Here we used a subset of the ICS data generated through the trial measuring 7 
functions: IFNγ, IL2, IL4, TNFα, MIP1β, CD107a and CD40L in CD4+ T cells in the 
presence and absence of stimulation with HIV-1 peptides, leading to 128 theoretical subsets 
in 71 subjects (T1:29, T2:15, T3:13, T4:14). However, the actual number of observed cell 
subsets is 107, and using the filtering criteria described above we reduced that number to 26 
subsets.
Statistical framework for modeling count data
Without loss of generality, we assume cell counts are obtained from I subjects under two 
conditions: (antigen)-stimulated and un-stimulated as depicted in Figure 1. Let M denote the 
number of markers measured, then in theory, there are KM=2M possible Boolean 
combinations defining functional cell subsets, depending on whether the marker is expressed 
or not. We let K (K ≤ KM) denote the actual number of cell subsets considered for statistical 
analysis (i.e. after filtering empty and very sparse cell subsets). The observed counts for the 
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K cell subsets in the stimulated and un-stimulated samples are represented by nsik and nuik, k 
= 1,…, K, i = 1,…, I, respectively, or represented as vectors we have nsi = (nsi1,…,nsiK)′ and 
nui = (nui1,…,nuiK)′. Then Nsi = Σk nsik and Nui = Σk nuik are the total number of cells for 
subject i in the stimulated and un-stimulated samples, respectively (Figure 1). Without loss 
of generality, we order the cell subsets such that the Kth category represents the subset where 
no cytokines are expressed, i.e. the degree of functionality is zero.
For a given subject i, we jointly model the cell counts under the two conditions using 
multinomial distributions: (nsi | psi) ~ MN(Nsi, psi ) and (nui | pui) ~ MN(Nui, pui), where psi 
and pui are the unknown proportions for the stimulated and un-stimulated paired samples, 
respectively. In order to detect a responding subject, as well as Ag-specific subsets within a 
subject, we consider two competing hypothesis: H0: pui = psi, and Ha: ∃k ∈ {1, …, K − 1} 
such that psik > puik. Under the null hypothesis H0, there is no difference in the proportion of 
cytokine producing cells between the stimulated and unstimulated samples, and thus the 
proportion vector parameter is shared across the two multinomial models. Under the 
alternative hypothesis Ha, some subsets show an increase in their proportions. We define the 
cell subsets that express at least one function and are different under Ha as Ag-specific 
subsets as the change in proportion is induced by the antigen stimulation. The Kth null 
category is not considered here, as a change there would only reflect a change in some other 
category since the proportion vector has to sum to one. This framework allows each subject 
to be responding in none, some or all of the subsets, and jointly models all the subjects and 
subsets to allow information sharing to improve the power in detecting rare signals. The 
ultimate objective is to automatically identify Ag-specific cell subsets for each subject.
Statistical model for detecting antigen specific polyfunctional T-cell subsets
In order to allow the automatic identification of Ag-specific cell subsets for each subject, we 
introduce a binary indicator, γik associated with each subject i and each category k, such that 
if the category is Ag-specific, γik = 1, otherwise γik = 0. In other words, when γik = 1, the 
(unknown) cell proportions (psik, puik) for the stimulated and un-stimulated samples are 
different, otherwise they are equal. The distribution of cell proportions can be specified 
easily conditional on the latent indicators, which is shown in Supplementary section: Priors. 
Our implementation of the COMPASS model uses an optimized Markov chain Monte Carlo 
(MCMC) algorithm allowing full exploration of the joint posterior distribution 
(Supplementary section: Posterior sampling). Then statistical inference about responding 
subsets across subjects, subsets or polyfunctionality degree would be based on the posterior 
summaries of the latent indicators, such as using the posterior mean, and/or FDR-
thresholded posterior probabilities. Our approach uses a Bayesian variable-selection prior, 
with a subset specific – but common across subjects – prior weight shared and estimated 
across all subjects. As a result, the inference automatically takes into consideration multiple 
comparisons16 across subjects.
Subject-level response probabilities
ICS assays are often used for determining vaccine responders based on the magnitude of 
Ag-specific T-cell responses. Current approaches for positivity tend to be univariate; a 
single cell-subset needs to be defined as an endpoint (e.g. cells expressing IL2 and/or IFNγ). 
Lin et al. Page 12
Nat Biotechnol. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Because COMPASS uses a Bayesian approach to jointly model all cell subsets, any 
posterior summary of interest is readily available. COMPASS can classify vaccine 
responders or MTB-infected individuals by computing subject-level response probabilities, 
defined as the probability that at least two (disjoint) cell subsets exhibit an Ag-specific 
response in that subject. The rationale is that antigen stimulation in subjects with antigen-
specific cells should induce changes in a variety of cell subsets, while non-specific 
responses are expected to be sporadic and noisy. Note that even though our subject-level 
response probabilities are computed based on two or more responding cell subsets, we still 
define the alternative hypothesis Ha (described above) as at least one difference, since 
COMPASS can return posterior probabilities for each subset, i.e. we really consider all 
possible alternative models.
Polyfunctionality and Functionality Score Definition
We introduce the functionality (FS) and Polyfunctionality PFS scores to summarize the 
response across the different cell subsets for each subject. The benefits of a single-number 
summary of subject-level response have been outlined elsewhere10. Primarily, it greatly 
facilitates statistical analysis, comparisons across treatment groups and correlation with 
outcome measures. We define the FS as the posterior mean of the average number of 
antigen-specific cell subsets among all measured subsets, irrespective of the degree of 
functionality:
Where γ̂ik is the posterior mean of γik estimated using MCMC (See Supplementary Text). 
The FS ranges from zero to one and measures the proportion of distinct cell subsets that are 
expressed for a given subject among all possible subsets.
The PFS is the mean of the posterior probabilities, weighted by the degree of functionality 
of the corresponding subset, and normalized by the total number of possible cell subsets that 
could be observed, given the number of markers considered:
Where, d(k) is the degree of functionality for cell subset k. The PFS ranges from zero to one. 
The normalization by the theoretical number of possible cell subsets facilitates the 
comparison of FS and PFS across different data sets, provided they utilize the same markers. 
It should be noted that the FS and PFS – based on the posterior probabilities – do not 
directly take into account the frequencies (i.e. magnitudes) of Ag-specific cells. The 
posterior probability summarizes all the evidence that a cell subset is Ag-specific by 
comparing the proportion of cytokine positive cells in the stimulated sample to the 
corresponding proportion in the control sample. Once there is enough evidence that the 
subset is indeed Ag-specific (i.e. the probability is one), the actual proportion of Ag-specific 
cells, which can be estimated as the difference in proportion between the stimulated and un-
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stimulated samples, is no longer relevant. In other words, two cell subsets with a probability 
of one will be treated equally in our approach, except for the degree of functionality that 
factors into the PFS even though they may have differing magnitude. Although, we could 
use the actual proportion of Ag-specific cells in our calculation (Supplementary text), we 
have found that it did not improve our analysis, and that in fact it decreased some of the 
correlation reported here (Supplementary Figures 11–12, Supplementary Table 4).
The PFS will assign a higher score to subjects with Ag-specific cell subsets of higher 
degree, whereas the FS will assign a higher score to subjects that exhibit Ag-specificity in 
more cell subsets irrespective of their degree of functionality. The two scores are 
complementary in the sense that the PFS emphasize the quality (i.e. the polyfunctionality) of 
Ag-specific cell subsets, whereas, the FS looks at the quantity of Ag-specific cell subsets. As 
an example, if we are considering 6 markers, two subjects may have the same PFS if one has 
a single degree 6 Ag-specific cell subset (PFS=0.286), while the other has Ag-specificity in 
all subsets with degree < 4 (PFS=0.286). The FS would distinguish between these, assigning 
score of 0.016 to the first subject, and a score of 0.651 to the latter.
Polyfunctionality index—The polyfunctionality index was calculated as described in 
Larsen et al15 using both uncorrected and background-corrected cell frequencies with the 
tuning parameter q set to 1, which is the equivalent of the PFS score where all subsets are 
weighted by their degree of functionality. Basically, for the uncorrected PI score we simply 
used the stimulated frequencies, psik, whereas for the corrected PI score, we used the 
background corrected frequencies defined as max(psik-puik,0). The two scores are referred to 
as PI and PI corrected in Supplementary Text. We have also tried other tuning parameter 
values including q=1.2 and q=2, and the results did not improve.
Correlate of risk analysis—All immune variables identified here were assessed as 
correlates of infection risk (CoR) by using the statistical methods specified in the original 
correlates study18. Briefly, for each immune biomarker, logistic regression accounting for 
the sampling design was used to estimate the odds ratio (OR) of infection, controlling for 
gender and baseline behavioral risk, and IgA levels.
RV144 primary analysis results
Six assays from the 17 different types of immune assays in the original RV144 study were 
selected as primary endpoints for optimal statistical power when adjusting for multiple 
comparisons. These selected primary variables included Env-specific plasma IgA, Env- 
specific plasma IgG binding avidity, gp70-V1V2-specific plasma IgG, neutralizing 
antibodies, ADCC (antibody dependent cell-mediated cytotoxicity) and Env-specific CD4+ 
T-cells. The major findings in a multivariate model including all six primary variables were 
that gp70-V1V2-specific plasma IgG inversely correlated with infection rate (odds ratio 
0.57, P=0.03, q=0.08), and Env-specific plasma IgA was a direct correlate of infection (odds 
ratio 1.54, P=0.03, q=0.08).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Overview of an ICS experiment. Blood samples are drawn from I subjects. A sample is split 
into aliquots that are subject to stimulation with antigen or are left non-stimulated as 
negative controls. After stimulation, whole PBMCs are labeled with fluorophore-conjugated 
antibodies against phenotypic (e.g. CD4, CD3, CD8, AVID/Live/Dead) and functional (e.g. 
IFNγ, IL2, TNFα, CD40L, IL17, IL4) markers (cells are permeabilized and intra-cellularly 
labeled for functional markers). The single-cell expression of each marker on each labeled 
cell is measured via flow cytometry, wherein cells pass in single-file through a flow cell and 
lasers of different wavelengths excite the fluorophores on the markers. A series of filters and 
detectors measure the emitted photons from the different fluorophores, providing a measure 
of intensity proportional to the amount of each protein expressed by each cell. After 
acquisition, data are processed and distinct cell populations of interest identified via a 
process termed ‘gating’, which describes identifying thresholds in multivariate space that 
classify each marker as either ‘positive’ (expressed) or ‘negative’ (not expressed). A 
COMPASS analysis assumes the ‘gating’ is given, and the COMPASS tool summarizes the 
number of cells expressing different combinatorial functional markers for specific 
phenotypic cell subsets (e.g. the number of CD4+ T cells expressing different combinations 
of cytokines). For M markers, this produces an I by 2M matrix of counts. COMPASS 
simultaneously models the counts for the paired stimulated and non-stimulated samples for 
each subject across all combinatorial functional cell subsets.
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Figure 2. 
(a) Heatmap of COMPASS posterior probabilities for the RV144 data set. Columns 
correspond to the different cell subsets modeled by COMPASS (shown are the 15 of 24 
subsets with detectable antigen-specific responses that had >5 cells in >2 subjects), color-
coded by the cytokines they express (white=“off”, shaded=“on”, grouped by color=“degree 
of functionality”), and ordered by degree of functionality from one function on the left to 
five functions on the right. Subsets with maximum posterior probabilities less than 0.005 are 
removed from the heatmap. Rows correspond to subjects (only shown are 226 vaccine 
recipients), which are ordered by their status: non-infected and infected, and by functionality 
score within each group. Each cell shows the probability that the corresponding cell-subset 
(column) exhibits an Ag-specific response in the corresponding subject (row), where the 
probability is color-coded from white (zero) to purple (one). (b) Boxplots of functionality 
and polyfunctionality scores stratified by HIV infection status in RV144 among 226 vaccine 
recipients. Non-infected individuals have higher scores than infected ones (Wilcoxon test p 
= 0.03 (FS), p = 0.01 (PFS). Both scores are inversely correlated with infection (Table 1).
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Figure 3. 
Functionality score vs. (a) proportion of expressed cytokines as measured by multiplex bead 
array and (b) IgG antibody binding in RV144. A set of 12 cytokines were measured by 
multiplex bead array. The proportion of detectable secreted cytokines was calculated in each 
individual and compared to the functionality score. The functionality score is significantly 
correlated with overall cytokine production (ρ=0.68, p-value < 2.2×10−16) and antibody 
binding (ρ=0.50, p-value=3.02×10−10). The fitted regression line from simple linear model 
is plotted in blue, and the 95% confidence interval is shown in grey.
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Figure 4. 
(a) Heatmap of COMPASS posterior probabilities for the TB data set. Columns correspond 
to the different cell subsets modeled by COMPASS (shown are the six of 22 and 19 subsets 
with detectable antigen-specific response that had >5 cells in >2 subjects), color-coded by 
the cytokines they express (white=“off”, shaded=“on”, grouped by color=“degree of 
functionality”), and ordered by degree of functionality from one function on the left to five 
functions on the right. Subsets with maximum posterior probabilities less than 0.1 are 
removed from the heatmap Rows correspond to 40 subjects, which are ordered by level of 
interferon-gamma release as measured by Quantiferon Test (QFT). Subjects with positive 
QFT test results are labeled as TB positive. Each cell shows the probability that the 
corresponding cell-subset (column) exhibits an Ag-specific response in the corresponding 
subject (row), where the probability is color-coded from white (zero) to blue (one) for MTB-
specific stimulation and red (one) for MTB-non-specific. A mix of blue and red (i.e. yellow) 
indicate a response to both stimulations. (b) Boxplots of functionality and polyfunctionality 
scores stratified by TB positive and TB negative for both TB-specific and non TB-specific 
stimulations.
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Figure 5. 
(a) Heatmap of COMPASS posterior probabilities for the HVTN078 data. Columns 
correspond to the different cell subsets modeled by COMPASS (shown are the 22 of 26 
subsets with detectable antigen-specific response and having >5 cells in >2 subjects), color-
coded by the cytokines they express (white=“off”, shaded=“on”, color=“degree of 
functionality”), and ordered by degree of functionality from one function on the left to five 
functions on the right. Rows correspond to 71 subjects ordered by treatment group: T1: 
NYVAC+Ad5, T2–T4: increasing doses of Ad5+NYVAC, and by functionality score within 
each group. Each cell shows the probability that a given cell-subset (column) exhibits an 
Ag-specific response in the corresponding subject (column), where the probability is color-
coded from white (zero) to purple (one). (b) Boxplots of functionality and polyfunctionality 
scores for CD4+ T cells stratified by treatment groups.
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Table 1
Estimated odds ratios for HIV-1 Infection risk for the subset specific responses as determined by logistic 
regression models that adjust for baseline risk category and gender in the RV144 case-control study. Only 
subsets with p-values less than 0.05 are shown here. Odds ratio are per one standard deviation for each 
variable and are adjusted for IgA level, gender and baseline behavioral risk score. Lower and upper limits of 
the 95% confidence intervals (CI) for the estimated ratios are also shown. Q-values are the FDR adjusted p-
values across all 17 considered variables.
Variable Odds ratio (95% CI) p-value q-value
Functionality score 0.62 (0.42, 0.91) 0.014 0.06
Polyfunctionality score 0.57 (0.38, 0.84) 0.005 0.05
IL4+IL2+CD40L+ 0.62 (0.43, 0.90) 0.013 0.06
TNFα+IFNγ+IL4+IL2+CD40L+ 0.58 (0.39, 0.86) 0.006 0.05
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